Is Oregon’s emerging psychedelic therapy already being monopolized into another cash cow for big pharma?
The history of ballot measures in Oregon developed from the state’s early populist leanings. The irony then for Ballot Measure 109, which was pushed with the promise of assisting veterans and people with addiction problems, is that Oregon’s psilocybin program is on course to provide little access for people of lower-income… solutions exist that could allow Oregon to remain a sanctuary for ethical psilocybin treatment… raise red flags regarding the revolving door between some researchers and private industry.
…the highly regulated nature of the emerging psilocybin program and outside financial interests are threatening to turn Oregon’s experiment into another cash cow for big pharma. An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products… predatory psilocybin patenting practices will only corner psilocybin for the very wealthy in the short term, and in the long term, create incentives to turn psilocybin into another industry that values profit over patient access.
Original Article (Greenlightlawgroup):
Psilocybin patenting and the threat to patient access
Artwork Fair Use: Demis Map Server, Little Mountain 5